Cantor Fitzgerald’s Vertex Pharmaceuticals VRTX Stock Holding History

Cantor Fitzgerald’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-35,945	Closed	-$12.5M	–	566
2023 Q3	$12.5M	Buy	35,945 +432	+1%	+$151K	0.33%	105
2023 Q2	$12.5M	Buy	35,513 +1,625	+5%	+$548K	0.29%	123
2023 Q1	$10.7M	Buy	33,888 +769	+2%	+$231K	0.23%	160
2022 Q4	$9.56M	Buy	+33,119	New	+$10.1M	0.21%	169

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Cantor Fitzgerald's VRTX Position: Q4 2023 in Review

Cantor Fitzgerald sold out of Vertex Pharmaceuticals (VRTX) in Q4 2023, closing a stake of 35,945 shares — an estimated $12.5M sold.

Cantor Fitzgerald first reported a position in VRTX in Q4 2022 and held it in 4 quarters. The position peaked at $12.5M in Q3 2023. 1,439 funds tracked by Wall St. Rank hold VRTX as of Q4 2023.

Cantor Fitzgerald reported no remaining Vertex Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Cantor Fitzgerald sold 35,945 Vertex Pharmaceuticals shares in Q4 2023, an estimated $12.5M.
Cantor Fitzgerald first reported a position in Vertex Pharmaceuticals in Q4 2022 and held it in 4 quarters.
Cantor Fitzgerald's Vertex Pharmaceuticals position peaked at $12.5M in Q3 2023.
1,439 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2023.

Based on Cantor Fitzgerald's 13F filing for Q4 2023, filed 14 Feb 2024.